Avvio wins Best Use of Technology Award

Avvio have again been recognised for their contribution to cutting edge technology in the hospitality industry after winning the Best Use of Technology Award at the 2018 Serviced Apartment Awards in London. Avvio CEO Frank Reeves “We were presented with the … Continued

C4X Discovery announces licensing agreement

Calculus portfolio company C4X discovery, a drug discovery and development company that uses cutting-edge technology to design and create drug candidates, has announced a licensing agreement with Indivior for addiction treatment. The announcement from C4X read as follows: C4X Discovery … Continued

XJump opens 4th site in Ameger, Denmark

Calculus backed trampoline park operator, Xjump, has opened the doors to its newest site in Ameger, Denmark. This represents Xjump’s 3rd site in Denmark and 4th in total, continuing their strategy of expansion across Scandinavia. Lee Mayall, Xjump CEO – … Continued

Calculus view on ‘significant’ VCT rule changes

Much attention has been paid to the changes made to EIS investing and understandably so – they represent a step change for the industry.  Less attention, however, has been paid to the changes made to VCT rules, which are far … Continued

UK leads the way for start-up investment

This is an exciting time for EIS growth investing – 45 new businesses are born in this country every hour. The UK now launches as many new businesses each year as the USA, despite the population of the US being … Continued

Calculus view on Royal Assent for EIS/VCT reforms

Calculus welcomes measures to focus EIS and VCT investing on genuine growth companies Government action to sharpen the focus of Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) investments to ensure the capital goes to entrepreneurial growth companies, has … Continued

Collagen Solutions Investor Evening

On Monday 26 February, Jamal Rushdy, CEO of Collagen Solutions gave an update to investors on the results of their study involving ChondroMimetic® and in particular the significance of the clinical data compared to current competitive procedures. Key data highlights from … Continued

Scancell investor presentation available to view

The leadership team of pioneering biotechnology company Scancell, which is developing new immunotherapy techniques to treat cancer, announced “exciting” progress when they addressed a seminar for investors and analysts on Friday 16th February. To view a copy of the presentation … Continued